The global advanced therapy medicinal products market is anticipated to grow at a significant CAGR of over 15% during the forecast period. The advanced therapy medicinal products have the potential to treat a range of degenerative disorders including conditions that don’t possess any treatment today. There has been significant progress in both basic and applied research of advanced therapy medicinal products including technical innovation and various scientific discoveries to promote advanced therapies.

Factors such as the prevalence of chronic diseases and genetic disorders across the globe coupled with the rising government investments in regenerative medicine research would fuel the global advanced therapy medicinal products market. Additionally, new product approvals and a growing pipeline of medical products are also anticipated to contribute to the growth of the market. However, ethical concerns related to advanced therapies such as the use of embryonic stem cells in R&D will serve as a major restrain for the advanced therapy medicinal products market. Moreover, the rising demand for organ transplantation all across the globe will create new opportunities for market growth during the forecast period.

Segmental Outlook 

The global advanced therapy medicinal products market is segmented on the basis of the type of therapy into cell therapy, Car-T therapy, gene therapy, tissue-engineered product. The cell therapy segment covers the analysis of stem cell therapy and non-stem cell therapy.

Global Advanced Therapy Medicinal Products Market Share by type of Therapy, 2018 (%)

Cell Therapy will be the largest segment by Type of Therapy

Cell therapy segment is anticipated to hold a significant share market share in the advanced therapy medicinal products market owing to increasing use in the cancer treatment all across the globe. Several products related to cell therapy have already secured approval in countries including the US, China, European countries, South Korea, Japan, Australia, Canada, and India. 

A substantial number of well-established pharma companies including pharma start-ups in combination with universities and hospitals are shifting their focus from conventional therapies to advanced therapies medicinal products, which in turn, is surging the segmental growth of the market. Further, increasing funding from governments as well as non-government organizations in order to support cell therapy clinical trials coupled with improving the laws for cell therapy manufacturing and implementation, is anticipated to drive the growth of the cell therapy segment.

Regional Outlooks

The global advanced therapy medicinal products market is further segmented on the basis of geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to hold a prominent share in the global advanced therapy medicinal products market. The increasing incidence of cardiovascular diseases in the region supports the growth of the advanced therapy medicinal products market over the forecast period. According to the CDC’s stats, around 647,000 Americans lose their life from heart disease each year.

Global Advanced Therapy Medicinal Products Market Growth, by Region 2019-2025

Asia-Pacific will augment with the fastest growth rate in the advanced therapy medicinal products market 

Asia-Pacific is anticipated to exhibit the fastest growth rate in the advanced therapy medicinal products market due to the aging population, increasing transplant needs per organ donation statistics, and the emergence of personalized medicine offers the potential for scientific achievements for advanced therapies medicinal products in the region.

Moreover, advanced therapy and medicinal products are anticipated to contain the cure of diseases such as Alzheimer's which is also driving research in the Asia-Pacific region. For instance, according to the Alzheimer's Association in 2020, in Japan, it is estimated that more than 4.6 million people are living with Alzheimer’s disease currently. Advancement of more consistent regulation policies and establishment of standards for products and their clinical application in the Asia-Pacific region will facilitate technology development and drive the market during the forecast period.

Market Players Outlook

Some of the key players operating in the global advanced therapy medicinal products market include Novartis International AG, Bluebird Bio Inc., UniQure N.V., Celgene Corp.,JCR Pharmaceuticals Co., Ltd.,Spark Therapeutics Inc., Gilead Lifesciences, Inc., MeiraGTx Holdings plc, Kolon TissueGene, Inc.,and others.The market players are considerably contributing to the market growth by adopting various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

For instance, MeiraGTx Holdings plc in March 2020, announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) designations to AAV-RPGR, MeiraGTx’s investigational gene therapy for the treatment of x-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. MeiraGTx and Janssen Pharmaceuticals, Inc. are jointly developing AAV-RPGR as part of a broader collaboration for the development and commercialization of gene therapies to treat inherited retinal diseases.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global advanced therapy medicinal products market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.